Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carlos Cabrera Galvez"'
Autor:
Manon A Simard, Carlos Cabrera-Galvez, Santiago Viteri, Felix Geist, Nadine Reischmann, Michael Zühlsdorf, Niki Karachaliou
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 57, Iss , Pp 101063- (2024)
MET inhibitors have demonstrated efficacy in treating patients with non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Advancements in spatial profiling technologies have unveiled the complex dynamics of the tumor microenviron
Externí odkaz:
https://doaj.org/article/3bf51d62f03b48e4a51b131b02e0e59d
Autor:
Xiuning Le, Luis Paz-Ares, Jan Van Meerbeeck, Santiago Viteri Ramirez, Carlos Cabrera Galvez, David Vicente Baz, Young-Chul Kim, Jin-Hyoung Kang, Christopher Stroh, Dilafruz Juraeva, Rolf Bruns, Gordon Otto, Andreas Johne, Paul K. Paik
Publikováno v:
Journal of Clinical Oncology. 40:9121-9121
9121 Background: Tepotinib, a potent, highly selective, oral, MET inhibitor, showed meaningful activity in patients (pts) with NSCLC with high-level METamp by LBx in VISION. Exploratory biomarker analyses are presented herein. Methods: Pts had 0–2
Autor:
Susana Cedres Perez, Garazi Serna, Juan David Assaf Pastrana, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Carlos Cabrera Galvez, Alberto Gonzalez-Medina, Roberta Fasani, Xavier Guardia, Javier Gonzalo, Caterina Carbonell, Joan Frigola, Ramon Amat, Ana Vivancos, Paolo Nuciforo, Enriqueta Felip
Publikováno v:
Journal of Clinical Oncology. 40:e20595-e20595
e20595 Background: MPM is an aggressive cancer associated with asbestos exposure. Chemotherapy has been a mainstay of therapy and recently immunotherapy has been associated with survival improvements. Chemotherapy and immunotherapy influence the tumo